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This issue of the journal presents a milestone in expanding coverage against cancers 
associated with human papillomavirus (HPV). Joura and coauthors’ report of a randomized 
controlled trial of 9-valent vs. quadrivalent HPV vaccine in over 14,000 young women found 
vaccine efficacy of nearly 97% against high-grade cervical/vulvar/vaginal disease related to 
types 31, 33, 45, 52, and 581. The intent-to-treat analysis found no benefit of 9-valent vs. 
quadrivalent vaccine, presumably because so many of the 16–26 year old study subjects had 
already been infected with the five additional HPV-types by the study’s onset. The rationale 
for vaccination at 11–12 years is to provide protection before HPV acquisition.
What HPV researchers talk about when they talk about “coverage” is the distribution of 
HPV-types in cancers. Earlier formulations targeted the most common oncogenic types, 16 
and 18, responsible for about 70% of cervical cancers. The 9-valent vaccine’s additional 
types are expected to target up to 15–20% more cervical cancers and 5–20% more of other 
HPV-related cancers23. While HPV-related cancer coverage can now expand, other types of 
coverage present ongoing challenges.
What many Americans talk about when they talk about “coverage” is health insurance. HPV 
vaccine has been included in the Vaccines for Children (VFC) program since 20064. The 
VFC entitles uninsured children through age 18 years to vaccines recommended by the 
Advisory Committee on Immunization Practices (ACIP) for free. Since 2010, the Affordable 
Care Act (ACA) requires private health insurers to cover HPV and other ACIP-
recommended vaccines and has prohibited copays or deductibles when vaccines are 
delivered by an in-network provider. On paper, insurance coverage for HPV vaccines is now 
comprehensive. The limited availability of in-network providers in some rural jurisdictions 
and persistence of some grandfathered plans not required to follow the ACA preventive care 
provisions represent remaining barriers to access. HPV vaccine is the most expensive series 
currently recommended in the VFC program5; private sector catalogue prices are even 
higher. Initial costs for clinicians to stock this product for privately insured patients while 
awaiting reimbursement and concerns regarding out-of-pocket expenses among those 
without access to in-network providers may mean that insurance coverage constraints inhibit 
vaccine uptake in practice if not statute.
What the immunization community talks about when we talk about “coverage” is the 
proportion of the targeted population that gets a vaccine. By any metric, HPV vaccine 
coverage in the US is a problem. At 57%, first dose HPV vaccine coverage among girls 13–
17 years old lags by ~20–25 percentage points compared with other vaccines recommended 
for 11–12 year olds6. If every time teenagers received another vaccine, they were offered and 
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accepted HPV vaccine, first dose coverage would exceed 90%7. Despite private doctors’ 
offices stocking vaccines, and parents and teens visiting the offices and accepting other 
immunizations, four out of ten adolescent girls have not even begun HPV vaccination. 
Formative research suggests parents hear mixed messages about HPV vaccination; 
pediatricians communicate less urgency and give weaker recommendations for this vaccine. 
When clinicians present HPV vaccine together with Tetanus-diphtheria-acellular pertussis 
and meningococcal vaccines and make strong recommendations, there is greater acceptance.
It’s possible a three-dose series is daunting to parents of teens and their clinicians, whether 
due to cost (even if borne by private insurance or the VFC program) or the difficulty of 
making three office visits during a stage when school and extracurricular activities can be 
all-consuming. Expanding in-network insurance coverage to pharmacies could present a 
convenient option for completion of multi-dose series during the teenaged years, but 
immunization data for these encounters should be made accessible to primary care 
physicians through immunization information systems. Regulatory authorities in several 
countries have approved two-dose series for young adolescents for both the quadrivalent and 
bivalent HPV vaccine based on non-inferior immunogenicity for two doses given six months 
apart8. The ACIP has reviewed available data for two-dose schedules and will review 
forthcoming data on the immunogenicity of alternative schedules for the 9-valent vaccine.
Even with the availability of another highly effective and safe HPV vaccine, now targeting 
additional cancer-causing virus types, vaccination of much higher proportions of preteens is 
needed. Otherwise, decades from now oncologists will still be talking about HPV-associated 
cancers with thousands of new patients every year. A few decades from now, it would be 
nice if we were able to tell a generation of adults who never developed HPV-associated 
cancers or pre-cancers that when they were teenagers, we had them covered.
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